['FLUVOXAMINE (CYP1A2 INHIBITOR)', '25 MG TWICE DAILY FOR 8 DAYS', '5-MG SINGLE DOSE', '+13%', '+29%', 'COADMINISTER WITH CAUTION THE FULL THERAPEUTIC DOSE OF FLUVOXAMINE WOULD BE EXPECTED TO CAUSE A GREATER INCREASE IN ASENAPINE PLASMA CONCENTRATIONS. AUC: AREA UNDER THE CURVE.', 'PAROXETINE (CYP2D6 INHIBITOR)', '20 MG ONCE DAILY FOR 9 DAYS', '5-MG SINGLE DOSE', '\xe2\x80\x9313%', '\xe2\x80\x939%', 'NO SAPHRIS DOSE ADJUSTMENT REQUIRED [SEE DRUG INTERACTIONS (7.2) ]', 'IMIPRAMINE (CYP1A2/2C19/3A4 INHIBITOR)', '75-MG SINGLE DOSE', '5-MG SINGLE DOSE', '+17%', '+10%', 'NO SAPHRIS DOSE ADJUSTMENT REQUIRED', 'CIMETIDINE (CYP3A4/2D6/1A2 INHIBITOR)', '800 MG TWICE DAILY FOR 8 DAYS', '5-MG SINGLE DOSE', '\xe2\x80\x9313%', '+1%', 'NO SAPHRIS DOSE ADJUSTMENT REQUIRED', 'CARBAMAZEPINE (CYP3A4 INDUCER)', '400 MG TWICE DAILY FOR 15 DAYS', '5-MG SINGLE DOSE', '\xe2\x80\x9316%', '\xe2\x80\x9316%', 'NO SAPHRIS DOSE ADJUSTMENT REQUIRED', 'VALPROATE (UGT1A4 INHIBITOR)', '500 MG TWICE DAILY FOR 9 DAYS', '5-MG SINGLE DOSE', '2%', '\xe2\x80\x931%', 'NO SAPHRIS DOSE ADJUSTMENT REQUIRED']